Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

Clinical trial NCT03441061 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT03441061

Sponsor

M.D. Anderson Cancer Center

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2018-02-15

Primary completion

2027-02-28

Enrollment

40

View on ClinicalTrials.gov